The diagnostic and prognostic value of interleukin-6 in patients with soft tissue sarcomas.

The diagnostic and prognostic value of interleukin-6 in patients with soft tissue sarcomas.
复制标题

白介素-6在软组织肉瘤患者中的诊断和预后价值。

DOI:
10.1038/s41598-017-08781-6
复制
发表时间:
2017-08-29
期刊:
影响因子:
4.6
通讯作者:
Sudo A
Sudo A
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Hagi T;Nakamura T;Iino T;Matsubara T;Asanuma K;Matsumine A;Sudo A

文献摘要

参考文献

被引文献

相似文献

全身性炎症的存在已被报道与软组织肉瘤(STS)患者的预后不良有关。细胞因子白细胞介素-6(IL-6)对肿瘤微环境中的各种细胞类型具有多效性作用。本研究的目的是确定血清IL-6水平是否可用于假设良性软组织肿瘤从STS的分化,并调查IL-6的生存和肿瘤学事件的STS患者的可能价值。回顾性分析99例手术切除患者的病历资料。STS患者血清IL-6水平(中位数:9.04 pg/ml)显著高于良性软组织肿瘤患者(3.31 pg/ml)。我们的分析证实肿瘤大小和IL-6水平是STS诊断的重要预测因子。接下来,我们研究了59例STS患者的IL-6水平与生存率之间的关系。C反应蛋白水平、血红蛋白水平和肿瘤分级与IL-6水平密切相关。肿瘤分级和IL-6水平仍然是影响生存和无事件生存的重要因素。我们认为,IL-6水平的测量可能是一个有用的方法,用于确定患者谁是在STS和肿瘤相关死亡的高风险。
The presence of systemic inflammation has been reported to be associated with poor prognosis in patients with soft tissue sarcoma (STS). The cytokine interleukin-6 (IL-6) has pleiotropic effects on various cell types in the tumor microenvironment. The aim of the present study was to determine whether serum IL-6 levels could be useful to assume the differentiation of benign soft tissue tumors from STS and to investigate the possible value of IL-6 for survival and oncological events in patients with STS. The medical records of 99 patients who underwent surgical resection were retrospectively reviewed. Serum IL-6 levels (median: 9.04 pg/ml) in patients with STS were statistically higher than those (3.31 pg/ml) in patients with benign soft tissue tumors. Our analyses confirmed that tumor size and IL-6 level were significant predictors of STS diagnosis. Next, we examined the relationship between IL-6 levels and survival in the 59 patients with STS. C-reactive protein levels, hemoglobin levels, and tumor grade were strongly correlated with IL-6 levels. Tumor grade and IL-6 level remained significant factors for survival and event-free survival. We suggest that measurement of IL-6 levels may be a useful method for identifying patients who are at a high risk of STS and tumor-related death.
DOI: 10.1200/jco.2003.02.026
发表时间: 2003-07-15
影响因子: 45.3
作者:
Weitz, J;Antonescu, CR;Brennan, MF
通讯作者: Brennan, MF
DOI: 10.1002/cncr.23615
发表时间: 2008-08-15
期刊: CANCER
影响因子: 6.2
作者:
Duffy, Sonia A.;Taylor, Jeremy M. G.;Teknos, Theodoros N.
通讯作者: Teknos, Theodoros N.
DOI: 10.1200/jco.1996.14.3.869
发表时间: 1996-03-01
影响因子: 45.3
作者:
Coindre, JM;Terrier, P;Contesso, G
通讯作者: Contesso, G
DOI: 10.1111/j.1349-7006.2007.00507.x
发表时间: 2007-07-01
期刊: CANCER SCIENCE
影响因子: 5.7
作者:
Fukuyama, Takashi;Ichiki, Yoshinobu;Yasumoto, Kosei
通讯作者: Yasumoto, Kosei
DOI: 10.1111/j.1464-410x.2008.07666.x
发表时间: 2008-09-01
期刊: BJU INTERNATIONAL
影响因子: 4.5
作者:
Lamb, Gavin W. A.;McArdle, Peter A.;McMillan, Donald C.
通讯作者: McMillan, Donald C.